Two of Intellia Therapeutics' Phase III gene therapy trials were put on clinical hold by the FDA in October 2025.
Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational BTK inhibitor, fenebrutinib, in RMS, ...
Faron Pharmaceuticals and City of Hope are to co-develop a Phase II for evaluating bexmarilimab in patients with r/r MDS.
Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy to treat ...
Medtech companies like BlueWind or Medtronic are increasingly investing in neuromodulation to treat urgency urinary ...
MSD has announced findings from the pivotal Phase III LITESPARK-022 trial, assessing the Keytruda-Welireg combination as adjuvant therapy for patients with clear cell RCC after nephrectomy.
Faster and more cost-effective trials support early-stage research in China driving the country's drug discovery engine.
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results